Brian Yum
Cardiovascular Disease · Webster, TXNPI 1326572231
Payments from drug & device makers
Across 251 payments — averaging $53.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Medtronic$769
- Actelion Pharmaceuticals US, Inc.$621
- Inari Medical, Inc.$596
- Boston Scientific$585
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$523
- plus $5K from 28 others
Across 2 payments — averaging $103.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$207
What the payments were for
- Travel & lodging$3,38225%
- Food & beverage$9,72173%
- Education$2872%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 46 | $4,955 |
| Medtronic | 16 | $769 |
| Actelion Pharmaceuticals US, Inc. | 26 | $621 |
| Inari Medical, Inc. | 4 | $596 |
| Boston Scientific | 5 | $585 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $523 |
| Angiodynamics, Inc. | 3 | $458 |
| Pfizer | 18 | $382 |
| Abiomed | 7 | $375 |
| Edwards Lifesciences | 5 | $361 |
| Biosense Webster, Inc. | 8 | $356 |
| Cardiva Medical, Inc. | 10 | $338 |
| Amgen | 12 | $309 |
| Teleflex LLC | 4 | $308 |
| Sanofi-aventis U.S. LLC | 7 | $263 |
| Novartis | 13 | $252 |
| Esperion Therapeutics, Inc. | 2 | $240 |
| W. L. Gore & Associates, Inc. | 6 | $239 |
| AstraZeneca | 11 | $185 |
| Heartflow, Inc. | 2 | $173 |
| Impulse Dynamics (USA) Inc. | 7 | $156 |
| Livanova USA, Inc. | 1 | $152 |
| Johnson & Johnson | 7 | $133 |
| Astellas Pharma US Inc | 3 | $123 |
| Philips North America LLC | 1 | $111 |
| Terumo Medical Corporation | 1 | $104 |
| Shockwave Medical, Inc | 4 | $81 |
| Boehringer Ingelheim | 3 | $71 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $41 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $33 |
| Cvrx, Inc. | 1 | $29 |
| Lexicon Pharmaceuticals, Inc. | 1 | $27 |
| Cordis US CORP. | 1 | $24 |
| Chiesi USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SUPERA$1,286
- ENSITE PRECISION$1,198
- FLOWTRIEVER CATHETER, S$707
- MitraClip$699
- CT THROMBECTOMY SYSTEM KIT$484
- AlphaVac$458
- COREVALVE EVOLUT R$418
- Impella$288
- NEXLIZET$240
- NEXLETOL$240
- EnSite Precision Cardiac Mapping System$207
- VersaCross Access Solution$185
- TandemHeart$152
- GORE CARDIOFORM Septal Occluder$150
- FFRct$148
- VenaSeal$140
- WATCHMAN Access System$132
- Repatha$125
- CARDIOMEMS$115
- TRAPLINER$113
How this compares
$13,390 in reported general payments places this provider in the 75th percentile of 1,515 cardiovascular disease providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 30 | $36,840 |
| Rosuvastatin Calcium | 38 | $2,087 |
| Ezetimibe | 15 | $1,768 |
| Metoprolol Succinate | 47 | $1,064 |
| Atorvastatin Calcium | 39 | $916 |
| Amiodarone Hcl | 11 | $899 |
| Losartan Potassium | 29 | $605 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 16 | $447 |
| Carvedilol | 12 | $351 |
| Spironolactone | 17 | $260 |
| Lisinopril | 14 | $187 |
| Metoprolol Tartrate | 17 | $146 |
| Amlodipine Besylate | 11 | $125 |
| Hydrochlorothiazide | 16 | $95 |
| Furosemide | 14 | $67 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $382 | $36,84030 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Webster
- Rakesh ShahWebster$507K
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.